[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531787":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":54,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":18,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":35,"whyStopped":18,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Haaglanden Medical Centre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HYPOPRIME treatment","EXPERIMENTAL","Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy",[13],"Radiation: HYPOPRIME treatment",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"RADIATION",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Leonard P Bokhorst, MD, PhD","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Ursula J Fisscher, PhD","CONTACT","0031889792357","u.fisscher@haaglandenmc.nl",{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},"Mirjam E Mast, PhD","+31 88 9792357","m.mast@haaglandenmc.nl",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Leidschendam","South Holland","2262 BA","Netherlands","NL",{"type":42,"coordinates":43},"Point",[44,45],4.39281,52.08167,{"lat":45,"lon":44},[48,51,52,53],{"name":49,"role":26,"phone":31,"phoneExt":18,"email":50},"Carmen P Liskamp, MD","c.liskamp@haaglandenmc.nl",{"name":30,"role":26,"phone":27,"phoneExt":18,"email":32},{"name":21,"role":26,"phone":18,"phoneExt":18,"email":18},{"name":49,"role":26,"phone":18,"phoneExt":18,"email":18},{"type":22,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Leonard Bokhorst","MD, PhD, radiation oncologist",[58],{"name":59,"class":6},"Tata Memorial Centre","100531787","towards-optimal-treatment-for-high-risk-prostate-cancer-100531787",false,"NCT06204341","Towards Optimal Treatment for High Risk Prostate Cancer","Towards Optimal Treatment for High Risk Prostate Cancer; Stereotactic Pelvic Radiotherapy with Focal Boost to the Primary Tumour","HYPOPRIME","Inclusion Criteria:\n\n* Men (aged ≥18 years of age) diagnosed within 6 months before inclusion with high risk prostate cancer:\n\n  * T3 based on digital rectal examination AND\u002FOR\n  * Grade \\>= 4 AND\u002FOR\n  * PSA \\>=20 ug\u002FL\n* Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)\n\nExclusion Criteria:\n\n* Prior pelvic radiotherapy\n* TransUrethral Resection of the Prostate (TURP) \\\u003C 3 months ago\n* Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc)\n* contraindications to MRI\n* no visible lesion on MRI in prostate for boost\n* no PSMA-PET scan\n* inflammatory bowel disease\n* metastatic disease (M1)\n* PSA \\>50\n* unsuitable for SBRT or WPRT\n* medical history of cancer other than basal cell carcinoma of the skin","MALE","18 Years",{"count":71,"type":72},207,"ESTIMATED","INTERVENTIONAL",[75],"NA","The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.\n\n* patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation)\n* the tumor will get a higher dose\n* androgen deprivation therapy will be reduced as much al possible preventing side effects\n\nResearchers will compare oncological outcome and toxicity.",[78],"High Risk Prostate Carcinoma",[80,81,82,83],"hypo fractionation","elective lymph node irradiation","focal boost","androgen deprivation therapy reduction","2024-09-10",{"date":86,"type":87},"2024-09-19","ACTUAL",{"date":89,"type":87},"2024-01-02",{"date":91,"type":72},"2032-12-18",{"name":5,"class":6},1]